Title of article
COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
Author/Authors
Aghili, Rokhsareh Endocrine Research Center - Institute of Endocrinology and Metabolism - University of Medical Sciences, Tehran, Iran , Honardoost, Maryam Endocrine Research Center - Institute of Endocrinology and Metabolism - University of Medical Sciences, Tehran, Iran , Khamseh, Mohammad E Endocrine Research Center - Institute of Endocrinology and Metabolism - University of Medical Sciences, Tehran, Iran
Pages
6
From page
147
To page
152
Abstract
The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated
comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensinconverting enzyme 2 (ACE2) acts as a host receptor for the virus. Therefore, medications acting on renin-angiotensin-aldosterone
system can lead to serious complications, especially in patients with diabetes and hypertension. To avoid this, other potential treatment
modalities should be used in COVID-19 patients with associated comorbidities.
Keywords
COVID-19 , Associated comorbidities , Treatment , ACE2 inhibitors , Type 2 diabetes
Journal title
Medical Journal of the Islamic Republic of Iran
Serial Year
2020
Record number
2562364
Link To Document